US Patent

US11400055 — Use of cannabidiol in the treatment of epilepsy

Method of Use · Assigned to GW Research Ltd · Expires 2035-10-13 · 9y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of cannabidiol (CBD) for treating treatment-resistant Tuberous Sclerosis Complex (TSC) characterized by seizures.

USPTO Abstract

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Drugs covered by this patent

Epidiolex (CANNABIDIOL) · Jazz Pharms Res

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3071`	—	Epidiolex

Patent Metadata

Patent number: US11400055
Jurisdiction: US
Classification: Method of Use
Expires: 2035-10-13
Drug substance claim: No
Drug product claim: No
Assignee: GW Research Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.